Compare VRTX & SHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | SHW |
|---|---|---|
| Founded | 1989 | 1866 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | RETAIL: Building Materials |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 85.2B |
| IPO Year | 1991 | N/A |
| Metric | VRTX | SHW |
|---|---|---|
| Price | $468.25 | $354.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 13 |
| Target Price | ★ $501.42 | $388.77 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.89% |
| EPS Growth | N/A | ★ 1.96 |
| EPS | ★ 14.22 | 10.23 |
| Revenue | $11,723,300,000.00 | ★ $23,275,600,000.00 |
| Revenue This Year | $10.93 | $2.82 |
| Revenue Next Year | $8.44 | $4.79 |
| P/E Ratio | ★ $32.42 | $34.83 |
| Revenue Growth | ★ 10.33 | 0.96 |
| 52 Week Low | $362.50 | $308.84 |
| 52 Week High | $519.68 | $379.65 |
| Indicator | VRTX | SHW |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 60.40 |
| Support Level | $429.00 | $346.86 |
| Resistance Level | $487.52 | $359.00 |
| Average True Range (ATR) | 13.28 | 9.10 |
| MACD | -0.92 | 1.53 |
| Stochastic Oscillator | 66.81 | 79.97 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.